Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 8/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.44 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59635 | 0.90 | KDR (0.60) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL442711 | 0.87 | CA1 (0.50) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL441291 | 0.84 | CA1 (0.55) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL423956 | 0.84 | PDGFRB (0.58) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL423204 | 0.83 | PDGFRB (0.61) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL418813 | 0.82 | MEN1 (0.59) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL424231 | 0.82 | RAB9A (0.55) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL15932598 | 0.81 | RAB9A (0.55) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL59604 | 0.80 | KMT2A (0.61) | CA1CA2CA9KDRPDGFRB | |
| SCHEMBL5675377 | 0.79 | PDGFRB (0.58) | CA1CA2CA9KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202372-B2 | Trisubstituted pyrido[2,3-D]pyrimidines, methods for preparing same and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2019-02-12 | — | — | US | disclosed |
| US-10202372-B2 | Trisubstituted pyrido[2,3-D]pyrimidines, methods for preparing same and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2019-02-12 | — | — | US | disclosed |
| EP-2885297-B1 | TRISUBSTITUTED PYRIDO[3,2-D]PYRIMIDINES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTICAL USES | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-10-11 | — | — | EP | disclosed |
| US-20150322070-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150203489-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | UNIVERSITE D'ORLEANS (FR) | 2015-07-23 | — | — | US | disclosed |
| US-20150203489-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | UNIVERSITE D'ORLEANS (FR) | 2015-07-23 | — | — | US | disclosed |
| EP-2885297-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014027081-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322070-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | CA1 3949/4885CA2 2586/4885CA9 4617/4885 |
| US-20150203489-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | DPYD, TYMP, RRM2B | CA1 3440/4885CA2 3265/4885CA9 2563/4885 |
| US-10202372-B2 | Trisubstituted pyrido[2,3-D]pyrimidines, methods for preparing same and therapeutic uses thereof | DPYD, TYMP, RRM2B | CA1 3440/4885CA2 3265/4885CA9 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.